News & Updates
Showing Urology articles
Showing
Cell-cycle progression tied to metastasis-free survival in high-risk prostate cancer
Cell-cycle progression, but not phosphatase and tensin homolog, appears to significantly elevate the risk of metastasis in men with prostate cancer following Cancer of the Prostate Risk Assessment Post-Surgical adjustment, suggests a study.
Cell-cycle progression tied to metastasis-free survival in high-risk prostate cancer
17 Nov 2022
Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
In the interim analyses of the phase III CHART trial, a combination regimen of ADT* and the novel second-generation androgen-receptor (AR) inhibitor rezvilutamide trumped the bicalutamide-ADT combination in terms of survival outcomes in individuals with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
14 Nov 2022
Testosterone, prostate volume influence lower urinary tract symptoms in prostate cancer
Among prostate cancer patients on androgen deprivation therapy (ADT), a small prostate and higher reductions in testosterone levels appear to aggravate storage symptoms, a recent study has found.
Testosterone, prostate volume influence lower urinary tract symptoms in prostate cancer
10 Nov 2022
T-cell exhaustion tied to post-BCG recurrence in bladder cancer
In patients with non-muscle-invasive bladder cancer (NMIBC), high-grade (HG) recurrence after bacillus Calmette-Guérin (BCG) treatment is associated with T-cell exhaustion, according to a study.
T-cell exhaustion tied to post-BCG recurrence in bladder cancer
07 Nov 2022
Carbapenem-sparing cephamycins effective in E coli-induced UTI
Cefmetazole and cefoxitin prove to be effective in the treatment of patients with urinary tract infections (UTIs) due to extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli, according to two separate studies presented at IDWeek 2022.